Isis Pharmaceuticals, Inc. announced today that it has launched a Phase 1 clinical trial for ISIS-DMPKRX. ISIS-DMPKRX is designed to reduce the production of toxic dystrophia myotonic-protein kinase (DMPK) RNA in cells, including muscle cells, for the treatment of Myotonic Dystrophy Type 1 (DM1).
Eric Jensen and his three-year-old son River will be cycling through the state of Iowa in the Des Moines Register’s Annual Great Bicycle Ride Across Iowa (RAGBRAI), July 20-26. The Jensens have named their ride “River’s Ride” and are dedicating their journey to families affected by DM.
Val Reeber - who is living with DM2 - and her husband and caregiver Bob share their story, and how DM2 has impacted their family.
Dr. John Day welcomed more than 100 people to the Stanford University School of Medicine's first annual California Myotonic Dystrophy Information Meeting on February 1, 2014.
This past weekend the MDF board of directors and staff met for two days of strategic planning in San Francisco to evaluate the work accomplished in 2013 and identify the project plan and objectives for 2014.